Combined lifestyle intervention reduces cardiometabolic risk in cancer survivors

Most studies focused on breast and prostate cancer survivors. The analysis found that CLIs were associated with improvements in body mass index (standardized mean difference [SMD] = −0.27), fasting blood glucose (SMD = −0.29), low-density lipoprotein cholesterol (SMD = −0.15), diastolic blood pressure (SMD = −0.12), and triglycerides (SMD = −0.26). All of these differences reached statistical significance, though the effect sizes were modest. Subgroup analyses showed little difference between different types of interventions, except that some designs performed better on blood glucose control. The authors note that future work should establish clearer definitions of what constitutes a combined intervention and explore digital health tools to improve adherence and sustainability.

The effect sizes here are genuinely modest—standardized differences of −0.12 to −0.29—so while statistically significant across thousands of participants, the absolute clinical benefit per person is likely measured in a few percentage points of improvement rather than dramatic shifts. However, the consistency across multiple cardiometabolic markers (five different measures all improved) suggests the approach works across the board, not just for one outcome. Notably, there was less variation in benefit between intervention types than you might expect: diet-plus-exercise worked about as well whether or not psychological support or alcohol counseling was added. This hints that the diet-exercise foundation carries most of the effect. Breast and prostate cancer survivors dominated the trials, so evidence in other cancer types is sparse. The authors emphasize that many studies lacked standardized definitions of what they meant by